Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting Jun 1, 2022
Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting Apr 4, 2022
Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference Dec 15, 2021
